Results 91 to 100 of about 3,518 (133)
Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration. [PDF]
Sci Rep, 2019 Yiu G +8 more
europepmc +1 more source
Sildenafil Citrate: Novel Therapy in the Management of Ovarian Torsion.
J Hum Reprod Sci, 2019 Ganla KN +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Sildenafil citrate-Associated priapism
Urology, 2000We report the first case of priapism associated with the use of sildenafil citrate. The patient was a 28-year-old man with mild erectile dysfunction after penile trauma who self-treated with a 100-mg dose of sildenafil citrate, resulting in low-flow priapism. After aspiration and intracorporal injection of alpha-agonists, the priapism resolved.
R L, Sur, C J, Kane
openaire +2 more sources
Sildenafil citrate: A therapeutic update
Clinical Therapeutics, 2001Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction. Recent studies and consensus reports have expanded our understanding of its efficacy, safety, contraindications, and drug interactions.This paper reviews recent studies of the efficacy ...
E G, Boyce, E M, Umland
openaire +2 more sources
Physicochemical Properties of Sildenafil Citrate (Viagra) and Sildenafil Base
Journal of Pharmaceutical Sciences, 2003Sildenafil citrate (Viagra) [I] and sildenafil base [II] are easily and unequivocally characterized by a set of physicochemical methods that include X-ray diffractometry, infrared spectroscopy, and thermal analysis. Monoclinic lattice constants: [I]: a = 26.98 A; b = 11.95 A; c = 16.68 A; beta = 106.97 degrees. [II]: a = 8.66 A; b = 34.27 A; c = 8.93 A;
Melnikov, P. +4 more
openaire +3 more sources
Viagra® (sildenafil citrate) and ophthalmology
Progress in Retinal and Eye Research, 2002Viagra (sildenafil citrate) improves penile erections in men with erectile dysfunction (ED) by selectively inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. It also exerts a minor inhibitory action against PDE6, which is present exclusively in rod and cone photoreceptors.
Alan, Laties, Eberhart, Zrenner
openaire +2 more sources
The Lancet, 1998
Sir—In your editorial on sildenafil citrate (Viagra), you state that “Public information to consumers and health professionals covers safety adequately, if not to the total satisfaction of consumer groups such as the US Public Citizen”. Although this editorial involved an internet search, we point out information that is not in the FDA-approved label ...
Sidney M Wolfe +2 more
openaire +1 more source
Sir—In your editorial on sildenafil citrate (Viagra), you state that “Public information to consumers and health professionals covers safety adequately, if not to the total satisfaction of consumer groups such as the US Public Citizen”. Although this editorial involved an internet search, we point out information that is not in the FDA-approved label ...
Sidney M Wolfe +2 more
openaire +1 more source
Overall cardiovascular profile of sildenafil citrate
The American Journal of Cardiology, 1999Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments for erectile dysfunction. During sexual stimulation, the cavernous nerves release nitric oxide (NO), which induces cyclic guanosine monophosphate (cGMP) formation and smooth muscle relaxation in the corpus cavernosum ...
R M, Zusman +3 more
openaire +2 more sources
Sildenafil citrate (Viagra(R))
Drugs of Today, 2000Sildenafil citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type V (PDE V), initially designated as compound 92-480-10 by Pfizer, was studied in the late 1980s as an antianginal. An unexpected side effect of the early clinical investigations was improved erectile function among the men studied.
openaire +2 more sources